人膀胱癌原代培养体外药敏试验的研究  

Evaluation of chemosensitivity of human bladder cancer determined by primary culture assay in vitro

作　　者：李艳芬[1] 田海梅[1] 李磊[2] 傅军[1] 曹冬艳[1] 李长岭[2] 王小兵[1] 李茉[1] 梁智[1] 程冬婉[1] 张伟[1] 

机构地区：[1]中国医学科学院肿瘤研究所肿瘤生物学检测中心 [2]中国医学科学院肿瘤医院泌尿外科

出　　处：《临床肿瘤学杂志》2006年第8期598-599,603,共3页Chinese Clinical Oncology

摘　　要：目的:探讨用ATP生物荧光肿瘤体外药敏检测技术(ATP-TCA)研究膀胱癌药敏的异质性和个体化疗的可行性。方法:用ATP-TCA检测来自45例初发和6例复发膀胱癌患者的手术标本对4种化疗药物的敏感程度。结果:51例标本中有49例获得药敏结果,可评价率为96·0%。最有活性的药物是吡柔比星,有43·8%(21/48)的标本对它表现强敏感;28·6%(14/49)的标本无强敏感药物;69·4%(34/49)的标本无耐药药物。结论:膀胱癌对抗癌药物的敏感程度存在着异质性。ATP生物荧光肿瘤药敏检测技术可用于为膀胱癌选择合适的化疗药物。Objective：To investigate the heterogeneity of chemosensitivity in bladder cancer using an ATP-tumor chemosensitivity assay （ATP-TCA） and the feasibility of individual chemotherapy. Methods： An ATP-tumor chemosensitivity assay （ATP-TCA） were used to determine the effect of 4 cytotoxic drugs in surgical specimens from 51 patients with primary （ n =45 ） or recurrent （ n =6） bladder cancer. Results：Evaluable test results were achieved in 49 of 51 patients. The evaluability rate was 96%. The most active drug in the assay was identified as pirarubicin, for 43.8% （21/48） specimens were super-sensitivity to it. 28. 6% specimens were not be super-sensitivity to any drugs tested, whereas 69.4% specimens were not to be resistant to any drugs tested. Conclusion ： There is the heterogeneity of the chemosensitivity in bladder cancer in vitro. The use of the ATP-TCA provides a method of selecting appropriate anti-cancer drugs in bladder cancer.

关 键 词：ATP生物荧光肿瘤药敏检测技术 膀胱癌 药物敏感性 

分 类 号：R737.14[医药卫生—肿瘤] R730.43[医药卫生—临床医学]